The global veterinary pharmacovigilance market size was valued at USD 1.03 billion in 2025 and is projected to grow from USD 1.17 billion in 2026 to USD 3.20 billion by 2034, registering a CAGR of 13.46% during the forecast period (2026–2034). North America dominated the veterinary pharmacovigilance marketwith a marketshare of 41.13% in 2025.
Veterinary pharmacovigilance refers to the science and activities involved in detecting, assessing, understanding, and preventing adverse effects with veterinary medicinal products. It ensures the safety, efficacy, and quality of pharmaceuticals, vaccines, biologics, and feed additives used in companion and livestock animals.
The veterinary pharmacovigilance market demand is driven by the expanding animal healthcare services, rising pet ownership, stringent regulatory requirements, and growing awareness of animal drug safety. Advancements in digital reporting technologies and increasing outsourcing activities are further driving veterinary pharmacovigilance market growth.
Download a Free Sample To learn more about this report,
Veterinary pharmacovigilance is shifting from manual case processing to AI-driven platforms that automate adverse event detection, literature screening, and signal management. This transition enables faster case assessments, improved regulatory compliance, and more efficient safety monitoring across large veterinary product portfolios. AI and machine learning tools also help identify emerging safety signals from multiple data sources, enhancing decision making for manufacturers and regulators.
The market is witnessing a transition from isolated safety databases to cloud-based pharmacovigilance ecosystems that enable centralized data management and real-time collaboration. This shift supports standardized adverse event reporting, streamlined regulatory submissions, and better coordination among pharmaceutical companies, CROs, and regulatory authorities. Cloud platforms also improve scalability and data accessibility for global pharmacovigilance operations.
The veterinary pharmacovigilance market forecasts investments directed toward AI-enabled adverse event monitoring platforms, cloud-based pharmacovigilance software, regulatory compliance automation, real-world safety data analytics, and integrated veterinary drug safety reporting systems.
In January 2025, Anivive secured a USD 20 million investment from Leonid Capital Partners to advance next-generation pet health technologies, expand manufacturing readiness, and accelerate veterinary therapeutic development. While the funding was not exclusively for pharmacovigilance, it supports the broader veterinary drug development ecosystem, where pharmacovigilance and post-market safety monitoring are integral
Increasing Regulatory Requirements for Veterinary Drug Safety and Expanding Animal Healthcare Industry Drives Market
The implementation of stricter pharmacovigilance regulations by authorities such as the European Medicines Agency, the US Food and Drug Administration, and other national regulatory agencies is driving demand for veterinary pharmacovigilance solutions. Regulatory frameworks require animal health companies to continuously monitor, document, and report adverse events associated with veterinary medicines throughout their lifecycle. The increasing emphasis on post-marketing surveillance, risk management, and regulatory compliance is encouraging pharmaceutical manufacturers to invest in advanced pharmacovigilance systems and specialized service providers, thereby driving market growth.
The continuous expansion of the global animal healthcare industry, coupled with increasing approvals of veterinary pharmaceuticals, vaccines, and biologics, is creating significant demand for comprehensive pharmacovigilance services. Growing pet ownership, rising livestock healthcare expenditure, and increasing development of innovative animal health products have expanded the volume of safety data requiring continuous monitoring and evaluation. As veterinary pharmaceutical pipelines grow and product commercialization accelerates across global markets, manufacturers are strengthening pharmacovigilance capabilities to ensure product safety, meet evolving regulatory requirements, and maintain public confidence in animal healthcare products.
Low Adverse Event Reporting Rates and Diverse Animal Species & Variable Clinical Responses Restrain Market Expansion
Unlike human healthcare, veterinary pharmacovigilance relies heavily on voluntary adverse event reporting by veterinarians, livestock producers, and pet owners, resulting in significant underreporting of safety incidents. The lack of comprehensive real-world safety data reduces the effectiveness of signal detection, delays identification of emerging safety risks, and limits the ability of regulatory authorities and pharmaceutical companies to make timely risk management decisions.
Veterinary medicines are administered across multiple animal species with distinct physiological characteristics, metabolic pathways, and treatment protocols. Variations in breed, age, production purpose, and environmental conditions further complicate causality assessments, increasing the complexity of pharmacovigilance activities and requiring extensive species-specific expertise, thereby restraining operational efficiency and increasing compliance costs.
Expansion of Digital Veterinary Health Platforms and Rising Biologics & Novel Veterinary Therapeutics Pipeline Offer Growth Opportunities to Market Players
The rapid adoption of digital veterinary health platforms is creating significant opportunities for veterinary pharmacovigilance providers. Electronic medical records, telemedicine platforms, and connected veterinary practice management systems are generating large volumes of real-world clinical data that can be integrated into pharmacovigilance workflows. As veterinary healthcare becomes increasingly digital, demand for intelligent pharmacovigilance platforms is expected to accelerate.
The expanding pipeline of veterinary biologics, monoclonal antibodies, gene therapies, and advanced vaccines is creating new opportunities for pharmacovigilance service providers and technology vendors. These innovative therapies require comprehensive post-marketing surveillance to evaluate safety, monitor rare adverse events, and comply with evolving global regulatory requirements. As animal health companies continue investing in next-generation therapeutics for companion and food-producing animals, the need for specialized pharmacovigilance solutions, evidence generation, and advanced risk management capabilities is expected to grow substantially.
Managing Increasing Volumes and Establishing Causality Across Diverse Animal Populations Challenges Market Growth
A major challenge for the veterinary pharmacovigilance market is efficiently managing the rapidly growing volume of safety data generated from veterinary clinics, animal hospitals, pharmaceutical companies, regulatory databases, scientific literature, and digital reporting platforms. Integrating diverse datasets while maintaining data quality, consistency, and regulatory compliance requires advanced technologies and significant operational resources.
Determining whether an adverse event is directly associated with a veterinary medicinal product is particularly complex due to the diversity of animal species, breeds, husbandry practices, concurrent diseases, and multiple medication use. Limited patient history, inconsistent clinical documentation, and variations in environmental and nutritional factors further complicate causality assessments.
The software segment is expected to grow at a CAGR of 14.21% during the forecast period, owing to increasing adoption of AI-powered signal detection, automated adverse event case processing, and cloud-based regulatory compliance platforms. These solutions improve workflow efficiency and enable centralized global safety data management for veterinary pharmaceutical companies.
The services segment is expected to grow at a CAGR of 14.70% during the forecast period due to rising outsourcing of aggregate reporting, benefit risk assessment, and multilingual pharmacovigilance operations. Organizations increasingly rely on specialized service providers to address regulatory complexity, optimize operational costs, and access experienced veterinary safety professionals.
In 2025, the in-house segment is expected to grow at a CAGR of 13.97% during the forecast period, as large animal health companies prioritize direct oversight of safety databases, confidential product information, and internal risk management processes.
The contract outsourcing segment is expected to grow at a CAGR of 14.36% during the forecast period, driven by increasing demand for scalable pharmacovigilance resources, 24/7 case processing capabilities, and region-specific regulatory expertise. Outsourcing also enables manufacturers to rapidly manage fluctuating safety workloads without expanding internal infrastructure.
The anti-infective segment accounted for a share of 43.36% in 2025 due to widespread use across companion and food-producing animals, resulting in higher adverse event reporting volumes requiring continuous monitoring. Frequent antimicrobial usage also necessitates enhanced surveillance for resistance patterns and product safety evaluation.
The biologics segment is expected to grow at a CAGR of 14.90% during the forecast period, driven by expanding approvals of monoclonal antibodies, recombinant vaccines, and immunotherapies for animal health. These advanced therapies require intensive post-marketing surveillance because of their complex mechanisms and evolving long-term safety profiles.
The companion animal segment accounted for a share of 52.39% in 2025, as increasing pet ownership and higher expenditure on advanced veterinary therapeutics generate greater pharmacovigilance reporting requirements. Companion animals also receive more specialized treatments requiring continuous safety monitoring throughout product lifecycles.
The livestock animal segment is expected to register a CAGR of 14.68% during the forecast period, driven by increasing disease prevention programs, extensive vaccine administration, and expanding use of production-enhancing veterinary medicines. Regulatory authorities also emphasize continuous monitoring of medicine safety to protect animal productivity and food safety.
North America: Market Dominance Led by Stringent Veterinary Drug Safety Regulations and Advanced Digital Pharmacovigilance Infrastructure
The North America veterinary pharmacovigilance market accounted for the largest regional share of 41.13% in 2025, driven by stringent veterinary drug safety regulations, widespread adoption of digital pharmacovigilance platforms, and the presence of leading animal health companies. The region benefits from well-established regulatory frameworks, high veterinary healthcare expenditure, and advanced post-marketing surveillance practices. Growing investments in AI-enabled pharmacovigilance technologies and increasing companion animal healthcare spending continue to strengthen regional market leadership.
The US veterinary pharmacovigilance market was valued at USD 368.57 million in 2025, driven by a robust animal health industry, increasing veterinary pharmaceutical innovation, and comprehensive regulatory oversight by the US Food and Drug Administration Center for Veterinary Medicine. Pharmaceutical companies are increasingly investing in automated adverse event reporting, cloud-based safety management systems, and AI-powered signal detection to improve regulatory compliance and operational efficiency.
The veterinary pharmacovigilance market in Canada was valued at USD 55.07 million in 2025, supported by growing awareness of veterinary medicine safety, increasing pet ownership, and expanding livestock healthcare initiatives. Regulatory oversight by the Veterinary Drugs Directorate of Health Canada encourages continuous monitoring of adverse drug events and strengthens post-market surveillance practices.
Asia Pacific: Fastest Growth Driven by Expanding Animal Healthcare Infrastructure and Strengthening Regulatory Frameworks
The Asia Pacific veterinary pharmacovigilance market is expected to grow at a CAGR of 15.29% during the forecast period, showcasing the fastest regional growth. Growth is supported by expansion of the animal healthcare sector, increasing veterinary pharmaceutical manufacturing, and strengthening regulatory requirements for drug safety monitoring. Governments across the region are enhancing pharmacovigilance frameworks to improve veterinary medicine safety and support growing livestock and companion animal populations. Rising digitalization of veterinary services and increasing investments by multinational animal health companies are further accelerating regional market growth.
The China veterinary pharmacovigilance market was valued at USD 58.80 million in 2025, supported by the country's expanding veterinary pharmaceutical industry, increasing livestock disease prevention programs, and growing regulatory oversight for veterinary medicinal products. Continuous investments in modern animal healthcare infrastructure and rising adoption of digital safety reporting systems are improving adverse event monitoring capabilities.
The India veterinary pharmacovigilance market was valued at USD 30.07 million in 2025, fueled by expanding livestock and poultry industries, rising pet ownership, and increasing domestic production of veterinary pharmaceuticals and vaccines. Regulatory initiatives promoting animal drug safety, along with growing awareness among veterinarians regarding adverse event reporting, are strengthening pharmacovigilance practices.
The Japan veterinary pharmacovigilance market was valued at USD 34.70 million in 2025, propelled by advanced veterinary healthcare infrastructure, stringent regulatory standards, and high adoption of innovative veterinary medicines for companion animals. Pharmaceutical companies are increasingly utilizing AI-enabled pharmacovigilance platforms and digital reporting systems to improve regulatory compliance and safety monitoring efficiency.
The veterinary pharmacovigilance market competitive landscape is moderately fragmented, with competition comprising global animal health companies, pharmacovigilance software providers, CROs, regulatory firms, and specialized pharmacovigilance service providers. Established players compete through comprehensive regulatory expertise, advanced pharmacovigilance platforms, and automation technologies. Emerging companies focus on AI-enabled safety monitoring, flexible outsourcing models, and cost-effective service offerings. The veterinary pharmacovigilance market ecosystem is shaped by evolving regulatory requirements, increasing adoption of digital safety monitoring, and rising demand for efficient post-marketing surveillance and risk management solutions.
May 2026: Veterinary Medicines Directorate launched a new digital adverse event reporting service for veterinarians and animal owners to improve the quality and efficiency of veterinary pharmacovigilance reporting.
August 2025: APVMA and Swissmedic signed a Memorandum of Understanding to strengthen cooperation on veterinary medicines regulation, including pharmacovigilance, post-market surveillance, scientific advice, and information sharing.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Pavan Warade is a Research Analyst with over 4 years of expertise in Technology and Aerospace & Defense markets. He delivers detailed market assessments, technology adoption studies, and strategic forecasts. Pavan’s work enables stakeholders to capitalize on innovation and stay competitive in high-tech and defense-related industries.
We are featured on:
sales@straitsresearch.com